INIS
diseases
100%
contraction
100%
regulations
100%
relaxation
100%
kidneys
100%
nitric oxide
71%
patients
57%
oxygen
57%
mitochondria
42%
levels
28%
humans
28%
sodium
28%
endothelium
28%
heart failure
28%
biological availability
28%
glucose
14%
rats
14%
damage
14%
control
14%
production
14%
adults
14%
accumulation
14%
hydrogen
14%
oxidation
14%
restoration
14%
scavenging
14%
Keyphrases
Chronic Kidney Disease
100%
Cardiomyocytes
100%
Empagliflozin
100%
Endothelial Regulation
100%
Cardiomyocyte Function
42%
Uremic Serum
42%
Mitochondrial Reactive Oxygen Species (mtROS)
28%
Endothelium
28%
Nitric Oxide Bioavailability
28%
Human Cardiac Microvascular Endothelial Cells
28%
Tyrosine
14%
Reactive Oxygen Species
14%
Reactive Oxygen Species Production
14%
Cardiovascular Events
14%
Beneficial Effects
14%
Endothelial Dysfunction
14%
Patients with Heart Failure
14%
Heart Failure with Preserved Ejection Fraction (HFpEF)
14%
Preserved Ejection Fraction
14%
Mitochondrial Oxidative Stress
14%
Adult Rats
14%
Diabetic Patients
14%
Co-culture System
14%
Nitric Oxide Production
14%
Cardiac Anomalies
14%
Endothelial Nitric Oxide
14%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
14%
Nitric Oxide Scavenging
14%
Cardiac Microvascular Endothelial Cells
14%
Sodium-hydrogen Exchanger
14%
Rat Ventricular Cardiomyocytes
14%
Nitric Oxide Level
14%
Medicine and Dentistry
Chronic Kidney Disease
100%
Cardiac Muscle Cell
100%
Empagliflozin
100%
Nitric Oxide
55%
Reactive Oxygen Species
44%
Endothelial Cell
33%
Uremia
33%
Bioavailability
22%
Diabetes Mellitus
11%
Endothelial Dysfunction
11%
Cardiovascular System
11%
3 Nitrotyrosine
11%
Ejection Fraction
11%
Heart Failure with Preserved Ejection Fraction
11%
Congestive Heart Failure
11%
Sodium Glucose Cotransporter 2 Inhibitor
11%
Sodium Proton Exchange Protein 1
11%